(Reuters) - The decision reverses a 2006 NICE opinion that Alimta, which is also known as pemetrexed disodium, was not cost-effective.
Read more at Reuters.com Government Filings News
Read more at Reuters.com Government Filings News
The Longs and the Shorts of my trading on the JSE. My thoughts, actions and rambelings while trading. The thing I love best!
No comments:
Post a Comment